查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930142

全球前列腺癌放射治療市場：市場規模、佔有率、成長率、行業分析、依類型、應用和地區劃分的考慮因素以及未來預測（2026-2034）

Prostate Cancer Radiation Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 189 Pages | 商品交期: 請詢問到貨日

價格

攝護腺癌放射治療市場的成長因素

受疾病盛行率上升、標靶放射性藥物應用日益廣泛以及核醫學持續進步的推動，全球前列腺癌放射治療市場預計將強勁增長。根據2025年的數據，預計2025年市場規模將達25.8億美元，2026年將達到33.6億美元。從長遠來看，隨著前列腺癌治療中對精準放射治療的臨床依賴性不斷增強，預計該市場將顯著增長，到2034年將達到242.8億美元。

此成長前景主要受全球前列腺癌負擔日益加重的驅動。 2022年全球新增前列腺癌病例約1,467,854例，凸顯了需要先進治療手段的病患群體不斷擴大。放射療法利用標靶放射性同位素摧毀癌細胞，同時最大限度地減少對正常組織的損傷，由於其更高的安全性和治療精準度，正日益取代傳統放射療法。

市場概覽及關鍵指標

依地區劃分，北美地區在前列腺癌放射治療市場中佔主導地位，預計到2025年將佔62.37%的市場佔有率，區域市場規模將達到16.1億美元。這一優勢得益於其先進的醫療基礎設施、完善的醫保報銷體係以及人們對癌症早期診斷和治療的高度重視。美國憑藉其廣泛的研究活動、快速的監管審批以及創新放射性藥物療法的普及，仍然是該地區最大的市場貢獻者。

歐洲佔第二大市場佔有率，這得益於系統性的癌症意識宣傳活動，例如一年一度的 "Movember" 活動以及標靶療法的日益普及。同時，亞太地區預計將成為成長最快的地區，這主要受人口快速老化、前列腺癌發病率上升以及澳洲、中國和日本等國家不斷擴大的腫瘤學研究計畫所驅動。

市場動態

市場驅動因素

人口老化是關鍵的成長驅動因素。攝護腺癌最常診斷於65歲以上的男性，約佔2023年所有確診病例的60.0%。預期壽命的延長、篩檢計畫的改進以及支持性的報銷政策正在促進治療普及和市場持續成長。

市場限制因子

儘管前景光明，但放射治療的高昂費用仍然是一個挑戰。例如，單次镥-177療法的費用可能超過5萬美元，這限制了其在對成本敏感地區的普及。此外，發展中國家缺乏專業的核子醫學基礎設施和複雜的監管要求也持續阻礙市場滲透。

市場機會

放射性同位素供應的策略聯盟是一個重要的機會領域。製藥公司與同位素生產商之間的合作正在提高供應鏈的穩定性，並加速下一代放射性藥物的臨床開發。這些合作有望支持市場的長期規模化和創新。

市場趨勢

影響市場的最重要趨勢之一是診療一體化（theranostics）的擴展，它將診斷影像和標靶治療相結合。這種個人化治療方法使臨床醫生能夠在進行放射性配體治療之前，利用分子影像識別合適的患者，從而改善治療效果並減少副作用。全球企業對診療一體化產品線的持續投入，印證了其在前列腺癌治療領域日益增長的重要性。

市場區隔洞察

依放射性同位素

镥-177憑藉其獲得多項監管批准和顯著的臨床療效，佔市場主導地位。 Pluvicto等產品進一步鞏固了該細分市場的地位。鐳-223的應用持續穩定成長，其他新興放射性同位素也透過持續的研究合作而獲得關注。

依類型

轉移性去勢抵抗性前列腺癌（mCRPC）細分市場佔最大的市場佔有率，這主要歸因於該疾病的嚴重性以及對先進標靶療法的強勁需求。隨著各公司日益關注早期幹預，非轉移性前列腺癌細分市場也不斷擴張。

依最終使用者劃分

截至2025年，擁有先進放射治療基礎設施和經驗豐富的腫瘤科醫生的醫院佔了最大的市場佔有率。隨著患者對強化、個人化癌症治療的需求日益增長，專科診所的發展勢頭強勁。

本報告詳細分析了2025年、2026年和2034年的市場規模和價值，並深入探討了市場動態、市場細分、區域展望、競爭格局和關鍵發展趨勢。報告全面展望了市場的未來發展軌跡，尤其關注監管審批、產品發布、合作趨勢以及精準放射治療在前列腺癌治療中不斷演變的作用。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區前列腺癌盛行率（2025 年）
  • 主要公司產品線分析
  • 替代療法概述
  • 主要公司新產品發布
  • 關鍵產業趨勢：併購、業務合作等
  • 新冠疫情的影響市場

第五章 全球前列腺癌放射治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依放射性同位素劃分
    • 鐳-223
    • 镥-177
    • 其他
  • 市場分析、洞察與預測：依類型劃分
    • 轉移性去勢抵抗性攝護腺癌
    • 非轉移性去勢抵抗性攝護腺癌
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區 (ROW)

第六章 北美攝護腺癌放射治療市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲前列腺癌放射治療市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區前列腺癌放射治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：世界其他地區（ROW）前列腺癌放射治療市場分析：洞察與預測（2021-2034）

第10章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
  • Novartis AG
  • Bayer AG
  • Telix Pharmaceuticals Limited
  • Ariceum Therapeutics
  • Radiopharm Theranostics Limited
  • Lantheus Holdings, Inc.
  • Clarity Pharmaceuticals
Product Code: FBI112713

Growth Factors of prostate cancer radiation therapeutics Market

The global prostate cancer radiation therapeutics market is positioned for strong expansion, supported by rising disease prevalence, growing adoption of targeted radiopharmaceuticals, and continuous advancements in nuclear medicine. According to the 2025 report year data, the market was valued at USD 2.58 billion in 2025 and is projected to reach USD 3.36 billion in 2026. Over the long term, the market is forecast to grow substantially and attain USD 24.28 billion by 2034, reflecting the increasing clinical reliance on precision radiation therapies for prostate cancer management.

The growth outlook is primarily driven by the escalating global burden of prostate cancer. In 2022, approximately 1,467,854 new prostate cancer cases were recorded worldwide, highlighting the expanding patient pool requiring advanced therapeutic interventions. Radiation therapeutics, which utilize targeted radioisotopes to destroy cancer cells while minimizing damage to healthy tissues, are increasingly preferred over conventional radiation techniques due to their improved safety and treatment precision.

Market Overview and Key Metrics

From a regional standpoint, North America dominated the prostate cancer radiation therapeutics market in 2025 with a market share of 62.37%, translating to a regional market size of USD 1.61 billion. This dominance is supported by advanced healthcare infrastructure, strong reimbursement frameworks, and high awareness levels regarding early cancer diagnosis and treatment. The United States remains the largest contributor within the region due to extensive research activities, rapid regulatory approvals, and widespread access to innovative radiopharmaceutical therapies.

Europe holds the second-largest share of the market, supported by structured cancer awareness initiatives such as annual Movember campaigns and rising adoption of targeted therapies. Meanwhile, Asia Pacific is projected to be the fastest-growing region, driven by a rapidly aging population, increasing prostate cancer incidence, and expanding oncology research programs across countries such as Australia, China, and Japan.

Market Dynamics

Market Drivers

A key growth driver is the expanding geriatric population. Prostate cancer is most commonly diagnosed in men aged 65 years and above, accounting for approximately 60.0% of total diagnosed cases in 2023. Increased life expectancy, improved screening programs, and supportive reimbursement policies are collectively contributing to higher treatment uptake and sustained market growth.

Market Restraints

Despite its promising outlook, the market faces challenges due to the high cost of radiation therapeutics. For example, a single dose of Lutetium-177-based therapy can cost over USD 50,000, which limits accessibility in cost-sensitive regions. Additionally, the lack of specialized nuclear medicine infrastructure and complex regulatory requirements in developing economies continue to restrict market penetration.

Market Opportunities

Strategic collaborations for radioisotope supply represent a major opportunity area. Partnerships between pharmaceutical companies and isotope manufacturers are improving supply chain stability and accelerating clinical development of next-generation radiopharmaceuticals. Such collaborations are expected to support long-term market scalability and innovation.

Market Trends

One of the most significant trends shaping the market is the expansion of theranostics, which integrates diagnostic imaging with targeted therapy. This personalized treatment approach allows clinicians to identify suitable patients using molecular imaging before administering radioligand therapies, improving treatment outcomes and reducing adverse effects. Increasing investments in theranostic pipelines by global players underscore its growing importance in prostate cancer care.

Segmentation Insights

By Radioisotope

The Lutetium-177 segment dominated the market due to multiple regulatory approvals and strong clinical efficacy. Products such as Pluvicto have strengthened this segment's position. Radium-223 continues to show steady adoption, while other emerging radioisotopes are gaining traction through ongoing research collaborations.

By Type

The metastatic castration-resistant prostate cancer (mCRPC) segment accounts for the largest market share, driven by higher disease severity and greater demand for advanced targeted treatments. The non-metastatic segment is also expanding as companies increasingly focus on early-stage intervention.

By End User

Hospitals held the leading share in 2025 due to their advanced radiotherapy infrastructure and skilled oncology professionals. Specialty clinics are gaining momentum as patients seek focused and personalized cancer care.

Competitive Landscape

The global prostate cancer radiation therapeutics market is highly consolidated. Leading players such as Novartis AG and Bayer AG account for a significant share, supported by approved products and strong R&D pipelines. Other notable participants include Telix Pharmaceuticals, Lantheus Holdings, Clarity Pharmaceuticals, Radiopharm Theranostics, and Ariceum Therapeutics, all of which are actively investing in next-generation radiopharmaceutical development.

Report Scope

The 2025 report provides a detailed analysis of market size and value for 2025, 2026, and 2034, along with in-depth insights into market dynamics, segmentation, regional outlook, competitive landscape, and key industry developments. The coverage emphasizes regulatory approvals, product launches, collaborations, and the evolving role of precision radiation therapies in prostate cancer treatment, offering a comprehensive view of the market's future trajectory.

Conclusion

The prostate cancer radiation therapeutics market is entering a phase of accelerated transformation, supported by strong clinical demand, rapid technological advancement, and expanding acceptance of targeted radiopharmaceuticals. With the market valued at USD 2.58 billion in 2025, projected to reach USD 3.36 billion in 2026, and forecast to surge to USD 24.28 billion by 2034, the outlook clearly reflects the growing clinical reliance on precision radiation therapies. High disease prevalence, particularly among men aged 65 years and above, and the increasing shift toward personalized medicine are reinforcing long-term demand. North America's dominance, holding 62.37% market share in 2025, highlights the importance of advanced healthcare infrastructure and favorable reimbursement environments, while Asia Pacific's rapid expansion signals emerging opportunities. Despite challenges related to high treatment costs and regulatory complexity, ongoing collaborations, theranostics adoption, and robust R&D pipelines from leading companies are expected to sustain strong momentum. Overall, the market is well-positioned for sustained expansion through 2034, driven by innovation, precision oncology trends, and rising global prostate cancer burden.

Segmentation By Radioisotope, Type, End-User, and Region

By Radioisotope * Radium-223

  • Lutetium-177
  • Others

By Type * Metastatic Castration-Resistant Prostate Cancer

  • Non-Metastatic Castration-Resistant Prostate Cancer

By End-User * Hospitals

  • Specialty Clinics
  • Others

By Region * North America (By Radioisotopes, Type, End-User, and Country)

    • U.S.
    • Canada
  • Europe (By Radioisotopes, Type, End-User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Radioisotopes, Type, End-User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Radioisotopes, Type, and End-User)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Market

5. Global Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 5.1.1. Radium-223
    • 5.1.2. Lutetium-177
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals
    • 5.3.2. Specialty Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 6.1.1. Radium-223
    • 6.1.2. Lutetium-177
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals
    • 6.3.2. Specialty Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 7.1.1. Radium-223
    • 7.1.2. Lutetium-177
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 8.1.1. Radium-223
    • 8.1.2. Lutetium-177
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals
    • 8.3.2. Specialty Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 9.1.1. Radium-223
    • 9.1.2. Lutetium-177
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 10.2.1. Novartis AG
    • 10.2.2. Bayer AG
    • 10.2.3. Telix Pharmaceuticals Limited
    • 10.2.4. Ariceum Therapeutics
    • 10.2.5. Radiopharm Theranostics Limited
    • 10.2.6. Lantheus Holdings, Inc.
    • 10.2.7. Clarity Pharmaceuticals

List of Tables

  • Table 1: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 2: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 3: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 4: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 6: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 8: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 10: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 11: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 12: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 14: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 15: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 16: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2021-2034
  • Table 18: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 19: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2021-2034

List of Figures

  • Figure 1: Global Prostate Cancer Radiation Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025 & 2034
  • Figure 3: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025 & 2034
  • Figure 5: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2025 & 2034
  • Figure 6: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025
  • Figure 7: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 8: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025
  • Figure 9: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 10: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025
  • Figure 11: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 12: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country, 2025
  • Figure 13: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2025 & 2034
  • Figure 14: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025
  • Figure 15: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 16: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025
  • Figure 17: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 18: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025
  • Figure 19: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 20: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 21: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2025 & 2034
  • Figure 22: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025
  • Figure 23: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 24: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025
  • Figure 25: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 26: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025
  • Figure 27: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2025 & 2034
  • Figure 30: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2025
  • Figure 31: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 32: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2025
  • Figure 33: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 34: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2025
  • Figure 35: Global Prostate Cancer Radiation Therapeutics Market Share (%), By Company, 2025